Loading

Atezolizumab (Tecentriq®)

Dokument Fact Sheet
Spezifizierung Lungenkarzinom, nicht-kleinzellig (NSCLC) » PD-L1 ≥50% TC or ≥10% IC mono » Erstlinie
Stand Juli 2021
Dies ist die aktuell gültige Version des Dokuments

1Atezolizumab, NSCLC, PD-L1 ≥50% TC or ≥10% IC mono, first line

1 N - number of patients3 PFS - progression-free survival in months5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/414 results for control, results for new therapy15 hazard ratio for new therapy21 TC – tumor cells, IC – immune cells

Kommentare